Updated with more information, stock price
Celldex has regained full rights to CDX-110 and says it intends to continue the drug's development. Pfizer decided to terminate the partnership over CDX-110 because the drug is "no longer a strategic priority" for the company, Celldex said.
Celldex shares were down $1.54, or 32%, to $3.24 in recent Friday trading.Celldex licensed CDX-110 to Pfizer in April 2008. The drug is designed to treat glioblastoma multiformae, or GBM, a form of brain cancer. A hint of acrimony between Celldex and Pfizer emerged earlier this summer over the speed and direction of CDX-110's development. At the June annual meeting of the American Society of Clinical Oncology, Celldex CEO Anthony Marucci expressed frustration that the company couldn't move faster to start a pivotal, phase III study of CDX-110 because Pfizer was in charge of the drug's clinical development. One prickly issue was how to design a randomized, controlled phase III study of CDX-110 in GBM patients -- a necessary requirement to get the drug approved. A previous attempt to conduct a randomized phase II study -- in which some patients receive CDX-110 and others receive a placebo or control treatment -- failed because patients were reluctant to enter a study in which there was a chance they wouldn't receive the experimental drug. Previous phase II studies of CDX-110 have produced some promising benefits for brain cancer patients, but the number of patients treated were relatively small and the studies lacked a control arm by which treatment with CDX-110 could be compared. A source close to Celldex says that Pfizer also likely reached the conclusion that CDX-110's commercial potential wasn't significant enough financially, especially after the merger with Wyeth. CDX-110 is designed to work only in a subset of patients who have GBM brain tumors with a variation of a more common protein receptor. Celldex said additional data from a phase II study of CDX-110 will be presented at a medical meeting in November. As of June 30, Celldex had $65.8 million in cash. Now that Pfizer has walked away from CDX-110, Celldex will need to use it own cash to fund the drug's future clinical trials. --Written by Adam Feuerstein in Boston.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV